AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca chief Pascal Soriot eyes record £28m pay bonanza
Pascal Soriot is already the highest-paid FTSE 100 chief executive, landing £17.7m last year at the Anglo-Swedish drugs giant.
www.thisismoney.co.uk
November 1, 2026 at 3:52 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
November 2, 2026 at 2:54 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
The three-year restructuring programme will redirect savings into a pipeline of more than 180 projects as the drugmaker seeks to reach $80bn in annual revenue by 2030.
www.easterneye.biz
October 31, 2026 at 11:13 AM
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a programme to save $1.5 billion (€1.34bn) a year to invest back into developing new medicines.
l.euronews.com
October 30, 2026 at 9:17 PM
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
A AstraZeneca reportou um aumento na receita e no lucro no terceiro trimestre, uma vez que as vendas expressivas de medicamentos oncológicos c...
valor.globo.com
October 30, 2026 at 1:09 PM
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Board approves conveyance of 82.028 acres in Rivanna Futures to EDA to enable AstraZeneca project
Albemarle County approved a resolution to convey approximately 82.028 acres (Land Bay 82) to the county Economic Development Authority, enabling the EDA to provide incentives and convey property to AstraZeneca, a project staff said entails a $4.5 billion investment and about 600 jobs.
citizenportal.ai
November 2, 2026 at 8:07 AM
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
AstraZeneca follows GSK with $1.5B annual savings push
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, including EMERALD-2.
endpoints.news
October 30, 2026 at 12:16 PM
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in oncology, cell therapy & AI.
endpoints.news
October 30, 2026 at 6:18 PM
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.
AstraZeneca, United Kingdom is hiring:
Senior Scientist in Data Science
#medicine #datascienceinoncology
Senior Scientist in Data Science
#medicine #datascienceinoncology
November 3, 2026 at 2:29 AM
AstraZeneca, United Kingdom is hiring:
Senior Scientist in Data Science
#medicine #datascienceinoncology
Senior Scientist in Data Science
#medicine #datascienceinoncology
November 2, 2026 at 9:38 AM
November 2, 2026 at 9:28 AM
The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system.
Western Pharma Giants Paid Millions to Russian Distributors Linked to Fraud, Whistleblower Report Says - The Moscow Times
Four major Western pharmaceutical companies paid tens of millions of dollars in unusually high bonuses to Russian middlemen to supply cancer drugs to state hospitals, according to whistleblower docume...
www.themoscowtimes.com
November 2, 2026 at 5:58 PM
The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system.
The FTSE 100 pharmaceutical company said the three-year programme would deliver $1.5bn in annual benefits
AstraZeneca announces $2bn restructuring to invest in drugs pipeline
www.thetimes.com
October 30, 2026 at 9:18 AM
The FTSE 100 pharmaceutical company said the three-year programme would deliver $1.5bn in annual benefits
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
news-area.com
November 1, 2026 at 8:58 PM
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | #biotechsky #pharma
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink
Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual savings by 2029. | Facing looming patent cliffs, AstraZeneca has launched a...
www.fiercepharma.com
October 31, 2026 at 1:58 PM
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | #biotechsky #pharma
That's the opposite of what your earlier comment said (Moderna's is an mRNA vaccine), but also, what are you talking about? The Moderna COVID vaccine was not "pulled from the market mid-pandemic." The AstraZeneca and J&J ones were.
November 3, 2026 at 7:15 PM
That's the opposite of what your earlier comment said (Moderna's is an mRNA vaccine), but also, what are you talking about? The Moderna COVID vaccine was not "pulled from the market mid-pandemic." The AstraZeneca and J&J ones were.
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
The three-year restructuring programme will redirect savings into a pipeline of more than 180 projects as the drugmaker seeks to reach $80bn in annual revenue by 2030.
www.easterneye.biz
October 31, 2026 at 11:30 AM
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
www.instagram.com/p/DehRw9QDQHQ/
Eftersom AstraZeneca har beslutat att avregistrera produkten globalt i slutet av 2027, utreder Läkemedelsverket nu ersättningsalternativ. Ett av alternativen är salbutamol i injektionsform vilket i dagsläget inte marknadsförs i 🇸🇪 men finns tillgängligt i bl.a. 🇩🇰.
Eftersom AstraZeneca har beslutat att avregistrera produkten globalt i slutet av 2027, utreder Läkemedelsverket nu ersättningsalternativ. Ett av alternativen är salbutamol i injektionsform vilket i dagsläget inte marknadsförs i 🇸🇪 men finns tillgängligt i bl.a. 🇩🇰.
November 2, 2026 at 2:28 PM
www.instagram.com/p/DehRw9QDQHQ/
Eftersom AstraZeneca har beslutat att avregistrera produkten globalt i slutet av 2027, utreder Läkemedelsverket nu ersättningsalternativ. Ett av alternativen är salbutamol i injektionsform vilket i dagsläget inte marknadsförs i 🇸🇪 men finns tillgängligt i bl.a. 🇩🇰.
Eftersom AstraZeneca har beslutat att avregistrera produkten globalt i slutet av 2027, utreder Läkemedelsverket nu ersättningsalternativ. Ett av alternativen är salbutamol i injektionsform vilket i dagsläget inte marknadsförs i 🇸🇪 men finns tillgängligt i bl.a. 🇩🇰.
AstraZeneca, United Kingdom is hiring:
Postdoctoral Fellow in Epigenetic Mechanisms of Anti-Cancer Drug Resistance
#postdoc #medicine #cancerbiology
Postdoctoral Fellow in Epigenetic Mechanisms of Anti-Cancer Drug Resistance
#postdoc #medicine #cancerbiology
November 3, 2026 at 2:06 AM
AstraZeneca, United Kingdom is hiring:
Postdoctoral Fellow in Epigenetic Mechanisms of Anti-Cancer Drug Resistance
#postdoc #medicine #cancerbiology
Postdoctoral Fellow in Epigenetic Mechanisms of Anti-Cancer Drug Resistance
#postdoc #medicine #cancerbiology
The filings are based on global data from the Phase III SAFFRON trial, which read out at ESMO last week.
EU, Japanese Regulators Reviewing AstraZeneca, HutchMed’s EGFR-MET Combo for Lung Cancer
EU, Japanese Regulators Reviewing AstraZeneca, HutchMed’s EGFR-MET Combo for Lung Cancer
ebx.sh
November 2, 2026 at 10:17 PM
The filings are based on global data from the Phase III SAFFRON trial, which read out at ESMO last week.